E-resources
Peer reviewed
-
Thennati, Rajamannar; Burade, Vinod; Rutter, Guy; Vilsbøll, Tina; Thorens, Bernard
Obesity (Silver Spring, Md.), 11/2022, Volume: 30Journal Article
Background: The potent and long-acting novel human glucagon-like peptide 1 receptor (GLP-1R) agonist (GLP-1RA); GL0034, selectively activates GLP-1R. Based on the anti-obesogenic and metabolic benefits of GLP-1RAs, we evaluated the efficacy of GL0034 in diet induced-obesity (DIO) mouse model. Methods: C57BL6/J mice (age 7 weeks) were fed with high fat pelleted diet for 12 weeks to induce obesity and glucose intolerance. DIO mice were administered placebo or GL0034 (6.25 pg/kg or 25 pg/kg) or semaglutide (50pg/kg) every alternate day (q2d) for 4 weeks. On day 29, biochemical parameters, liver lipid and histology were evaluated. NAS-score was calculated as the sum of the scores for steatosis (0-3), lobular inflammation (0-3), and ballooning (0-2), with a total range of 0 to 8. Statistical evaluation was performed using Prism 5 software, where ·p<0.05, ··p<0.01 and ···p<0.001 vs. placebo and #p<0.05, ##p<0.01 and ###p<0.001 vs. semaglutide. Semaglutide was synthesized in-house. Results: DIO mice treated with GL0034 (6.25 pg/kg and 25 pg/kg) and semaglutide (50 pg/kg) demonstrated reduction in body weight of 0.4%, 10.4%··· and 14.9%··· and concomitant fat mass 11.0%, 29.8%··· and 39.1%··· respectively. Insulin levels were decreased from 10.7 (±2.0) ng/mL to 10.4 (±1.3), 6.0··· (±0.6), and 5.7··· (±1.0) ng/mL. Triglycerides levels were reduced from 40.9(±3.5) mmol/kg to 31.1··· (±3.3), 20.1··· (±1.3), and 18.0··· (±1.8) mmol/ kg respectively and low-density lipoprotein cholesterol were reduced from 1.34(±0.27) mmol/kg to 0.91·· (±0.17), 0.64··· (±0.05), and 0.57··· (±0.06) mmol/kg, respectively. The circulating levels of alanine aminotransferase (ALT) were significantly more reduced with GL0034 than with semaglutide treatment: 56%···#, 54%···# and 34% ···, respectively, for the three treatment groups vs. the placebo group. Further steatosis score was 1.0···, 0.3··· and 0.1··· as against 1.9 of placebo. Lobular inflammation grade of 0.7#, 0.4···### and 1.3 was observed vs. 0.9 of placebo. The observed NAS total score of 1.7···, 0.7···# and 1.4··· respectively vs. 2.7 of placebo. Conclusions: Our study demonstrates that, GL0034, even at lower doses, improves plasma and liver biochemical markers and histopathological changes. The efficacy of GL0034 was similar or superior to semaglutide at 2-8-fold lower doses in ameliorating the steatohepatic condition.
![loading ... loading ...](themes/default/img/ajax-loading.gif)
Shelf entry
Permalink
- URL:
Impact factor
Access to the JCR database is permitted only to users from Slovenia. Your current IP address is not on the list of IP addresses with access permission, and authentication with the relevant AAI accout is required.
Year | Impact factor | Edition | Category | Classification | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Select the library membership card:
If the library membership card is not in the list,
add a new one.
DRS, in which the journal is indexed
Database name | Field | Year |
---|
Links to authors' personal bibliographies | Links to information on researchers in the SICRIS system |
---|
Source: Personal bibliographies
and: SICRIS
The material is available in full text. If you wish to order the material anyway, click the Continue button.